Jaime King's Fertility Journey: What It Would Actually Cost a Non-Celebrity

What Jaime King Has Actually Said About Her Fertility

Jaime King has not hidden her diagnosis or her grief. She spoke publicly about losing multiple pregnancies before carrying her sons to term, describing the experience in a 2015 interview as "the most painful thing I've ever been through." She named endometriosis and PCOS as the underlying conditions her doctors identified. She has also referenced IVF as the intervention that helped her conceive.

That level of candor is rare and clinically useful. When a public figure names specific diagnoses rather than vague "fertility struggles," it gives other women language to bring to their own appointments.

What endometriosis and PCOS together mean for fertility

Endometriosis affects approximately 10% of women of reproductive age worldwide, though estimates run higher in infertility populations because the condition often goes undiagnosed for years. PCOS affects 6 to 12% of U.S. Women of reproductive age by CDC estimates.

Having both conditions simultaneously is not common but it happens. The two disorders pull fertility in opposite directions in some ways. PCOS typically produces many follicles but impairs ovulation and egg quality. Endometriosis can distort pelvic anatomy, damage the ovarian cortex, and create an inflammatory environment hostile to implantation. Together, they complicate every stage of the IVF process, from stimulation to retrieval to transfer.

The diagnostic delay problem

Women with endometriosis wait an average of 7 to 10 years from symptom onset to diagnosis, according to data published in Fertility and Sterility. That delay has direct fertility consequences. Each year of untreated endometriosis can reduce ovarian reserve. If King's timeline followed the population average, she may have been dealing with undiagnosed disease through most of her twenties. That context matters when you hear her describe years of loss before a successful pregnancy.

The Clinical Picture: What Doctors Would Do

A woman presenting today with King's reported profile, meaning documented endometriosis, PCOS, a history of pregnancy loss, and a desire for biological children, would go through a structured evaluation before any treatment began.

Initial workup

• Ovarian reserve testing: Day 3 FSH, estradiol, anti-Müllerian hormone (AMH), and antral follicle count (AFC) via transvaginal ultrasound. AMH is particularly informative in PCOS, where it tends to run high, and in endometriosis, where it can be falsely reassuring until ovarian cysts have caused irreversible damage.
• Hysterosalpingogram (HSG) or saline-infusion sonohysterography: To rule out tubal occlusion or uterine abnormalities from endometriosis adhesions.
• Laparoscopy: In moderate-to-severe endometriosis, surgical staging via laparoscopy may be recommended before IVF. ASRM guidelines note that surgical treatment of endometrioma before IVF can improve access to follicles but may also reduce ovarian reserve.
• Partner evaluation: Semen analysis to rule out a combined factor.
• Recurrent pregnancy loss panel: If multiple losses have occurred, a thrombophilia screen, karyotype of both partners, and uterine evaluation are standard.

Ovarian stimulation in PCOS: the hyperstimulation risk

Women with PCOS face a specific risk during IVF stimulation: ovarian hyperstimulation syndrome (OHSS). Because PCOS ovaries contain many antral follicles, they can over-respond to gonadotropins, producing dozens of follicles and triggering a dangerous fluid shift.

A 2016 meta-analysis in Human Reproduction found OHSS rates in PCOS patients undergoing IVF to be significantly higher than in unaffected women. Current protocols use low-dose antagonist cycles, letrozole priming, or GnRH agonist triggers instead of hCG triggers to reduce this risk. Freeze-all strategies, where all embryos are cryopreserved and transferred in a later cycle, are now standard practice in high-OHSS-risk patients.

A staged decision framework for women with both diagnoses

For a woman with PCOS plus endometriosis, the decision tree at a good reproductive endocrinology practice typically looks like this:

1. Stage endometriosis surgically if there is an endometrioma larger than 4 cm or if pelvic anatomy is significantly distorted.
2. Optimize metabolic status before stimulation. In women with PCOS who are insulin-resistant, metformin (500 to 2,000 mg/day) may be added to reduce OHSS risk and improve endometrial receptivity, though evidence is mixed. A Cochrane review found metformin combined with gonadotropins reduced OHSS risk without clearly improving live birth rates in all PCOS subgroups.
3. Use an antagonist stimulation protocol with conservative dosing.
4. Plan for freeze-all if OHSS risk is elevated.
5. Add preimplantation genetic testing for aneuploidies (PGT-A) if recurrent pregnancy loss is part of the history, though this remains debated in women under 35 with good prognosis.
6. Transfer in a medicated frozen embryo transfer (FET) cycle once the ovaries have recovered.

What Medications Are Involved and What They Cost

IVF is not one drug. It is a sequence of injected and oral medications across several weeks, each with its own cost and side-effect profile.

The standard medication stack

| Medication | Purpose | Typical dose | Average retail cost per cycle | |---|---|---|---| | FSH (follitropin alfa or beta, e.g., Gonal-f, Follistim) | Ovarian stimulation | 150 to 300 IU/day x 8 to 12 days | $2,500, $5,000 | | LH or hMG (e.g., Menopur) | Co-stimulation, especially in poor responders | 75 to 150 IU/day | $1,000, $2,000 | | GnRH antagonist (e.g., Cetrotide, Ganirelix) | Prevent premature ovulation | 0.25 mg/day for ~5 days | $500, $900 | | GnRH agonist trigger (e.g., Lupron) | Final maturation trigger in PCOS | Single 1 to 2 mg dose | $200, $400 | | Progesterone (vaginal or IM) | Luteal support post-retrieval | Variable duration | $300, $800 | | Estradiol (for FET cycles) | Endometrial preparation | Patches or oral | $100, $300 |

Total medication cost per cycle ranges from roughly $4,500 to $9,000 at retail prices. Mark Cuban's Cost Plus Drugs and specialty fertility pharmacies have reduced some costs; for example, follitropin alfa (Gonal-f 450 IU cartridge) is listed at Cost Plus for a fraction of the brand price, though not all medications are available there.

Pregnancy and lactation considerations for IVF medications

This section is required reading before any cycle begins.

Gonadotropins (FSH, hMG) are used to produce the pregnancy, not during it. They are discontinued at or before egg retrieval. No teratogenicity data exists for their use during an established pregnancy because they are not used that way in IVF protocols.

Progesterone supplementation continues through 8 to 12 weeks of pregnancy in most IVF protocols to support the corpus luteum before the placenta takes over. ACOG acknowledges that vaginal progesterone is used to support early IVF pregnancies, though data specifically on luteal support formulations in pregnancy is largely observational.

GnRH agonists (Lupron): If used as a downregulation agent before stimulation (long Lupron protocol), it must be stopped before the pregnancy is established. Lupron is classified as FDA Pregnancy Category X based on animal data showing fetal harm, though human IVF data is reassuring because it is used only in the pre-conception phase.

Metformin: If continued into pregnancy for PCOS-related miscarriage prevention, metformin crosses the placenta. It is not teratogenic in human data. The MiG trial (NEJM, 2008) found metformin safe and effective in gestational diabetes management, and some reproductive endocrinologists continue it through the first trimester in high-risk PCOS patients. Lactation: metformin is excreted in breast milk at low levels; the AAP considers it compatible with breastfeeding.

Women who do not achieve pregnancy after an IVF cycle and who are using any hormonal medications should discuss reliable contraception with their provider before any off-cycle period, particularly if they are on agents that could harm an unplanned pregnancy.

What It Costs Without a Celebrity Income

Let's be specific. IVF in the United States is expensive in a way that policy mostly ignores.

Per-cycle cost breakdown (U.S., 2024)

• Monitoring (bloodwork and ultrasounds): $1,500, $3,000
• Egg retrieval procedure + anesthesia: $3,500, $5,500
• Embryo culture and laboratory fees: $2,000, $4,000
• Embryo cryopreservation (if applicable): $500, $1,000
• Frozen embryo transfer: $3,000, $5,000
• PGT-A (per embryo biopsied): $250, $600 per embryo
• Medications: $4,500, $9,000

Total per retrieval cycle with one fresh or frozen transfer: $15,000, $25,000.

The CDC's 2021 ART Surveillance Report found that the national average live birth rate per IVF transfer in women under 35 was approximately 50%. That means many women will need more than one transfer, and some will need more than one retrieval cycle.

If a woman needs two retrieval cycles and three transfers before a live birth, total costs can reach $45,000, $60,000 before factoring in ancillary testing, genetic counseling, or treatment for underlying endometriosis.

Insurance coverage: the state-by-state lottery

As of 2024, 21 states have laws requiring some level of IVF coverage, though mandates vary enormously. New York, Illinois, and New Jersey have among the most comprehensive mandates. States like Texas, Florida, and Georgia have no mandate at all.

Even in mandate states, employer self-insurance plans (governed by ERISA, not state law) may opt out. Women in those plans, or in no-mandate states, pay out of pocket.

What actually reduces cost

• Mini or minimal stimulation IVF: Lower doses of injectables, lower medication cost, but typically fewer eggs retrieved.
• Shared-risk or refund programs: Some clinics offer multi-cycle packages with partial refunds if no live birth occurs. Read the fine print on exclusion criteria.
• Fertility grants: RESOLVE: The National Infertility Association maintains a list of fertility grants for low-income applicants.
• Academic medical center clinics: Often charge 20 to 30% less than private fertility boutiques.
• State Medicaid expansion: Does not typically cover IVF, but may cover the diagnostic workup.

Life Stage Matters: How This Changes Across the Reproductive Years

Jaime King conceived her sons in her mid-thirties. That age bracket is clinically significant, and her experience cannot be directly mapped onto every woman who identifies with her story.

In your 20s with PCOS and endometriosis

Ovarian reserve is typically highest. OHSS risk in PCOS is greatest. Surgical staging of endometriosis before IVF may be worth the short-term ovarian reserve hit because you have time. A 2014 study in Fertility and Sterility found that women under 35 with stage I, II endometriosis had IVF outcomes similar to matched controls.

In your 30s (the most common window for diagnosis and treatment)

Ovarian reserve is declining, particularly if endometriosis has been present for years. The urgency to preserve embryos increases. This is also the window where the combination of PCOS high-follicle-count and declining egg quality can produce chromosomally abnormal embryos at higher rates, making PGT-A a more meaningful conversation.

Perimenopause and beyond

Endometriosis often quiets after menopause due to falling estrogen, but it can reactivate on hormone therapy. Women with a history of endometriosis who are considering HRT in perimenopause should use estrogen plus progestogen (not estrogen alone) even after hysterectomy, because residual endometrial tissue can respond to unopposed estrogen. ACOG guidance supports this practice.

PCOS does not disappear at menopause. Metabolic sequelae, including insulin resistance, elevated androgen levels, and increased cardiovascular risk, persist and may worsen. Women with PCOS entering perimenopause need metabolic surveillance, not just reproductive follow-up.

Who This Path Is Right For, and Who Should Think Differently

Women most likely to benefit from IVF with this profile

• Documented tubal occlusion or severe pelvic adhesions from endometriosis
• Male factor infertility co-existing with female factor
• Failed 3 to 6 months of ovulation induction plus intrauterine insemination (IUI)
• Age 38 or older with documented declining ovarian reserve
• Recurrent pregnancy loss with embryo banking and PGT-A as the goal

Women for whom IVF might not be the first step

• Women under 35 with PCOS and no tubal factor may achieve pregnancy with letrozole (Femara) 2.5 to 7.5 mg on cycle days 3 to 7, which the ASRM now recommends over clomiphene as first-line ovulation induction in PCOS. The PPCOS II trial in the New England Journal of Medicine found letrozole produced a live birth rate of 27.5% vs. 19.1% for clomiphene in women with PCOS.
• Women with stage I, II endometriosis and open tubes may have a reasonable chance with IUI cycles before moving to IVF.
• Women with severe endometriosis who have not yet had a laparoscopic evaluation may benefit from surgical staging first, especially if a large endometrioma is present.

The evidence gap: what we do not know

Women with the specific combination of endometriosis plus PCOS are underrepresented in IVF outcome studies, which typically enroll patients with one primary diagnosis. A 2021 review in the Journal of Clinical Medicine noted the lack of prospective RCT data specifically in dual-diagnosis patients. Most guidance on this population is extrapolated from single-diagnosis trials. That means your reproductive endocrinologist is making judgment calls informed by, but not directly dictated by, trial data. Asking your RE specifically how they approach PCOS with concurrent endometriosis, and what their clinic's outcomes look like in that subgroup, is a reasonable and fair question.

A Note on Emotional Labor and Mental Health Costs

The financial costs of IVF are documented. The psychological costs are less often quantified but real.

A 2011 study in Fertility and Sterility found that women undergoing IVF reported anxiety and depression scores comparable to those of women with cancer or cardiac disease. The hormonal fluctuations of stimulation cycles, including rapidly rising estrogen followed by a sharp post-retrieval drop, exacerbate mood changes. Progesterone-heavy luteal phases can cause bloating, fatigue, and irritability that interfere with work and relationships.

Jaime King has spoken about the grief of pregnancy loss specifically. If you have experienced recurrent loss, standard IVF counseling may not be sufficient. Ask your clinic whether they have a licensed therapist with perinatal loss experience on staff or on referral. RESOLVE's peer-led support network offers free group support.

Specific Questions to Ask Your Reproductive Endocrinologist

Before your first IVF consultation, prepare these:

1. Given my AMH, AFC, and endometriosis stage, what is your clinic's expected egg yield per retrieval for someone with my profile?
2. Do you recommend surgical staging of my endometriosis before starting, or is my anatomy compatible with direct IVF?
3. What OHSS risk mitigation protocol will you use given my PCOS?
4. What is your clinic's live birth rate per transfer for women my age with my diagnosis combination?
5. Does your clinic report outcomes to the CDC's SART registry, and can I look up your clinic's SART data?
6. What is your policy on single embryo transfer, and how do you balance that against my recurrent loss history?
7. If I need donor eggs in the future, what does that pathway look like at your clinic?

CDC's SART data lookup allows you to compare clinic-specific success rates before you commit to a provider.